跳至主要内容
临床试验/ISRCTN87786644
ISRCTN87786644已完成未知

A randomised trial in relapsed ovarian cancer, early treatment based on Cancer Antigen (CA) 125 levels alone versus delayed treatment based on conventional clinical factors

Medical Research Council (MRC) (UK)0 个研究点目标入组 1,400 人开始时间: 2000年4月6日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
1,400

研究概览

简要总结

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • 1. Histologically confirmed epithelial ovarian, fallopian tube or serous primary peritoneal carcinoma
  • 2. In complete remission with a normal CA125 since first-line platinum containing chemotherapy
  • 3. A normal CA125 result within 4 weeks of registration onto the trial
  • 4. Patient in confirmed remission (based on physical gynaecological examination) within 6 weeks of registration onto the trial
  • 5. Able to attend regular follow-up and have regular blood tests
  • 6. Local laboratory able to blind CA125 results from clinicians
  • 7. No concomitant or previous malignancy within 5 years which is likely to interfere with the protocol treatments or comparisons, except with concomitant or previous non-melanoma skin cancer
  • 8. Informed consent from the patient

排除标准

  • Previous malignancy within 5 years

研究者

发起方
Medical Research Council (MRC) (UK)

相似试验

A randomised trial in relapsed ovarian cancer,... | 临床试验